(Q77983372)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

title

Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

1 reference

1 reference

7

H D White

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

author name string

J K French

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

T A Hyde

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

H Patel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

D J Amos

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

S C McLaughlin

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

B J Webber

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

language of work or name

English

0 references

publication date

1 July 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

Journal of the American College of Cardiology

9 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

9 December 2019

page(s)

62-69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10399993%20AND%20SRC:MED&resulttype=core&format=json

Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction

9 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

GISSI-2 and the heparin controversy

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge. The European Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Long-term survival in 618 patients from the Western Washington streptokinase in myocardial infarction trials

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Long-term prognostic importance of patency of the infarct-related coronary artery after thrombolytic therapy for acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

TIMI frame count: a quantitative method of assessing coronary artery flow

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Coronary arteriography; method of presentation of the arteriogram report and a scoring system

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Design features and baseline characteristics of the LIPID (long-term intervention with pravastatin in ischemic disease) study: A randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto-1 study. The GISSI Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Sustained benefit at 10-14 years follow-up after thrombolytic therapy in myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I Angi

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Should all occluded infarct-related arteries be opened?

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Prognostic significance of maximal exercise testing after myocardial infarction treated with thrombolytic agents: the GISSI-2 data-base. Gruppo Italiano per lo Studio della Sopravvivenza Nell'Infarto

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021

Prevention of one-year vein-graft occlusion after aortocoronary- bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS0735-1097%2899%2900166-7

7 January 2021